CRYSTALLINE FORM OF ANDROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREOF

Provided are a crystalline form of an androgen receptor inhibitor and a preparation method thereof. In particular, provided are type I crystal of (S)-4-(3-(4-(2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-carbonyl-2-thioimidazolin-1-yl)-2-(trifluoromethyl)benzonitrile (a compound of formula (I)) and a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: ZHONG, Liang, GUO, Changshan, WU, Guaili, LU, Yun
Format: Patent
Sprache:eng ; hun
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator ZHONG, Liang
GUO, Changshan
WU, Guaili
LU, Yun
description Provided are a crystalline form of an androgen receptor inhibitor and a preparation method thereof. In particular, provided are type I crystal of (S)-4-(3-(4-(2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-carbonyl-2-thioimidazolin-1-yl)-2-(trifluoromethyl)benzonitrile (a compound of formula (I)) and a preparation method thereof, wherein the method comprises: 1) any crystal form or amorphous form of the compound as shown by formula (I) is added to an appropriate amount of an organic solvent, heated and dissolved until clear, following by being cooled down and crystallized, wherein the organic solvent is selected from any one of esters, ketones, nitriles and ethers which have 5 or less carbon atoms, or a mixed solvent thereof; and 2) the crystal is filtered, washed and dried. The obtained type I crystal of the compound of formula (I) has a good chemical stability and crystal form stability, and the crystallization solvent used has a low toxicity and residue, and can be better used for clinical treatment.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_HUE050459TT2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>HUE050459TT2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_HUE050459TT23</originalsourceid><addsrcrecordid>eNqNikEKwjAQAHPxIOof1gcIRe3BY0w3JtDuhnV78FSKxJO0hfp_VPABnmZgZmnIye2qtq4jIXiWBtiDpUr4ggSCDpOyQKQQz_FrnwZJMFmxGpmgQQ1cgQYUZL82i0f_nPPmx5XZelQXdnkauzxP_T0P-dWFFouyOJYn1f3hn-cNPRIvSg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>CRYSTALLINE FORM OF ANDROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREOF</title><source>esp@cenet</source><creator>ZHONG, Liang ; GUO, Changshan ; WU, Guaili ; LU, Yun</creator><creatorcontrib>ZHONG, Liang ; GUO, Changshan ; WU, Guaili ; LU, Yun</creatorcontrib><description>Provided are a crystalline form of an androgen receptor inhibitor and a preparation method thereof. In particular, provided are type I crystal of (S)-4-(3-(4-(2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-carbonyl-2-thioimidazolin-1-yl)-2-(trifluoromethyl)benzonitrile (a compound of formula (I)) and a preparation method thereof, wherein the method comprises: 1) any crystal form or amorphous form of the compound as shown by formula (I) is added to an appropriate amount of an organic solvent, heated and dissolved until clear, following by being cooled down and crystallized, wherein the organic solvent is selected from any one of esters, ketones, nitriles and ethers which have 5 or less carbon atoms, or a mixed solvent thereof; and 2) the crystal is filtered, washed and dried. The obtained type I crystal of the compound of formula (I) has a good chemical stability and crystal form stability, and the crystallization solvent used has a low toxicity and residue, and can be better used for clinical treatment.</description><language>eng ; hun</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20201228&amp;DB=EPODOC&amp;CC=HU&amp;NR=E050459T2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25563,76318</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20201228&amp;DB=EPODOC&amp;CC=HU&amp;NR=E050459T2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ZHONG, Liang</creatorcontrib><creatorcontrib>GUO, Changshan</creatorcontrib><creatorcontrib>WU, Guaili</creatorcontrib><creatorcontrib>LU, Yun</creatorcontrib><title>CRYSTALLINE FORM OF ANDROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREOF</title><description>Provided are a crystalline form of an androgen receptor inhibitor and a preparation method thereof. In particular, provided are type I crystal of (S)-4-(3-(4-(2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-carbonyl-2-thioimidazolin-1-yl)-2-(trifluoromethyl)benzonitrile (a compound of formula (I)) and a preparation method thereof, wherein the method comprises: 1) any crystal form or amorphous form of the compound as shown by formula (I) is added to an appropriate amount of an organic solvent, heated and dissolved until clear, following by being cooled down and crystallized, wherein the organic solvent is selected from any one of esters, ketones, nitriles and ethers which have 5 or less carbon atoms, or a mixed solvent thereof; and 2) the crystal is filtered, washed and dried. The obtained type I crystal of the compound of formula (I) has a good chemical stability and crystal form stability, and the crystallization solvent used has a low toxicity and residue, and can be better used for clinical treatment.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNikEKwjAQAHPxIOof1gcIRe3BY0w3JtDuhnV78FSKxJO0hfp_VPABnmZgZmnIye2qtq4jIXiWBtiDpUr4ggSCDpOyQKQQz_FrnwZJMFmxGpmgQQ1cgQYUZL82i0f_nPPmx5XZelQXdnkauzxP_T0P-dWFFouyOJYn1f3hn-cNPRIvSg</recordid><startdate>20201228</startdate><enddate>20201228</enddate><creator>ZHONG, Liang</creator><creator>GUO, Changshan</creator><creator>WU, Guaili</creator><creator>LU, Yun</creator><scope>EVB</scope></search><sort><creationdate>20201228</creationdate><title>CRYSTALLINE FORM OF ANDROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREOF</title><author>ZHONG, Liang ; GUO, Changshan ; WU, Guaili ; LU, Yun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_HUE050459TT23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; hun</language><creationdate>2020</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>ZHONG, Liang</creatorcontrib><creatorcontrib>GUO, Changshan</creatorcontrib><creatorcontrib>WU, Guaili</creatorcontrib><creatorcontrib>LU, Yun</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ZHONG, Liang</au><au>GUO, Changshan</au><au>WU, Guaili</au><au>LU, Yun</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>CRYSTALLINE FORM OF ANDROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREOF</title><date>2020-12-28</date><risdate>2020</risdate><abstract>Provided are a crystalline form of an androgen receptor inhibitor and a preparation method thereof. In particular, provided are type I crystal of (S)-4-(3-(4-(2,3-dihydroxypropoxy)phenyl)-4,4-dimethyl-5-carbonyl-2-thioimidazolin-1-yl)-2-(trifluoromethyl)benzonitrile (a compound of formula (I)) and a preparation method thereof, wherein the method comprises: 1) any crystal form or amorphous form of the compound as shown by formula (I) is added to an appropriate amount of an organic solvent, heated and dissolved until clear, following by being cooled down and crystallized, wherein the organic solvent is selected from any one of esters, ketones, nitriles and ethers which have 5 or less carbon atoms, or a mixed solvent thereof; and 2) the crystal is filtered, washed and dried. The obtained type I crystal of the compound of formula (I) has a good chemical stability and crystal form stability, and the crystallization solvent used has a low toxicity and residue, and can be better used for clinical treatment.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; hun
recordid cdi_epo_espacenet_HUE050459TT2
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title CRYSTALLINE FORM OF ANDROGEN RECEPTOR INHIBITOR AND PREPARATION METHOD THEREOF
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T11%3A12%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ZHONG,%20Liang&rft.date=2020-12-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EHUE050459TT2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true